

Beiersdorf (BEI.XETRA) is trading at 76.58 EUR.
What happened
The COVID-19 outbreak in early 2020 dealt an immediate blow. Sales dropped sharply, especially in travel retail where luxury brands like La Prairie were heavily exposed, forcing the company to pull its full-year guidance. Recovery came quickly though. By 2021, demand normalized and selective cosmetics rebounded strongly, helping margins find their footing again.
The real inflection arrived in 2023–2024. Management reported record sales, laid out a profitable-growth roadmap, and committed material capital back to shareholders—a larger dividend plus a €500m buyback program. Meanwhile, e-commerce and luxury-brand investments were accelerating.
How the market saw it
In 2020, investors treated Beiersdorf as defensive consumer care with acute near-term risk. The narrative shifted in 2021–2022 as core brands stabilized and margins recovered; the luxury exposure still meant periodic volatility, but the quality-compounder story took hold. By 2023–2024, the re-rating was unmistakable: profitable growth with premium upside became the frame as results, margins and shareholder returns all delivered.
The price action
The panic sell-off in March–May 2020 gave way to a sustained recovery through 2021. The next phase—2021 through 2022—saw the stock consolidate in sideways-to-volatile ranges as macro headwinds and travel-retail normalization worked themselves out. From 2023 onward, an uptrend reasserted itself alongside improving fundamentals and the capital-return program.
Beiersdorf competes directly with multinational beauty and consumer-goods giants—L'Oréal, Unilever, Procter & Gamble, Henkel, and Shiseido—across skincare and personal care, while nimble niche brands nip at pricing from below [1][5]. This competitive squeeze limits room for price increases and margin growth, and the company navigates the usual headwinds: geography, retail channels, input costs—each one capable of shifting both operations and financials in unexpected directions [8][1].
Beiersdorf operates in a crowded space, competing with L'Oréal, Unilever, Procter & Gamble, Johnson & Johnson, and Estée Lauder across both mass and premium skin and personal care channels globally. The company faces persistent headwinds from competitors with greater marketing firepower and distribution reach, while navigating shifting consumer preferences, the acceleration of digital retail, and increasingly stringent regulatory oversight around dermatological claims and product substantiation across different markets.
| Company | Ticker |
|---|---|
| L'Oréal S.A. | OR.PA |
| The Procter & Gamble Company | PG.NYSE |
| Johnson & Johnson | JNJ.NYSE |
| Estée Lauder Companies | EL.NYSE |
Receive hand-picked stock recommendations with detailed analyses every week
Start Free Trial| Period | Beiersdorf Aktiengesellschaft | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | -26.89% | -20.92% | -21.90% |
| 3M | -18.25% | -12.85% | -13.88% |
| 6M | -15.40% | -10.43% | -13.13% |
| 1Y | -35.05% | -37.83% | -52.31% |
| 3Y | -34.76% | -82.99% | -99.84% |
| 5Y | -12.00% | -65.35% | -85.82% |
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHow the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 25.2 | 2.3 | 1.9 | 20.4 |
| 1Y ago | 16.2 | 1.4 | 3.1 | 11.9 |
| 3Y ago | 23.9 | 2.1 | 13.9 | 34.1 |
| 5Y ago | 23.5 | 1.9 | 11.9 | 12.7 |
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.00 EUR | — | 0.84% |
| 2025 | 1.00 EUR | 0.84% | |
| 2024 | 1.00 EUR | 0.74% | |
| 2023 | 0.70 EUR | 0.57% | |
| 2022 | 0.70 EUR | 0.74% | |
| 2021 | 0.70 EUR | 0.78% | |
| 2020 | 0.70 EUR | 0.74% | |
| 2019 | 0.70 EUR | 0.76% | |
| 2018 | 0.70 EUR | 0.76% | |
| 2017 | 0.70 EUR | 0.77% | |
| 2016 | 0.70 EUR | 0.88% | |
| 2015 | 0.70 EUR | 0.87% | |
| 2014 | 0.70 EUR | 0.99% | |
| 2013 | 0.70 EUR | 1.03% | |
| 2012 | 0.70 EUR | 1.33% |
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 9.85B | 9.85B | 9.45B | 8.80B | 7.63B |
| Operating income (EBIT) | 1.35B | 1.30B | 1.10B | 1.22B | 980.00M |
| Net income | 939.00M | 912.00M | 736.00M | 755.00M | 638.00M |
| Free cash flow | 373.00M | 794.00M | 424.00M | 249.00M | 580.00M |
| Total assets | 12.85B | 13.01B | 12.63B | 12.35B | 11.30B |
| Equity | 8.60B | 8.47B | 8.32B | 7.79B | 6.87B |
| Net debt | -983.00M | -941.00M | -1.03B | -722.00M | -757.00M |